Profile: Flamel Technologies SA (FLML.O)
30 Jan 2015
Flamel Technologies SA, incorporated on July 21, 1990, is a pharmaceutical company. The Company’s focus is on the development of safer and more efficacious formulations and other medical needs in the process. As of April 7, 2014 Micropump platform applied to sodium oxybate in a First-in-Man (FIM) clinical study in healthy volunteers. The Company’s lead products include Bloxiverz and Coreg CR.
Bloxiverz (Neostigmine Methylsulfate Injection) is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.
Coreg CR, the lead product uses the Company’s Micropump drug delivery platform. Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate), a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors. Coreg and Coreg CR are the only beta blockers indicated for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction.
Flamel Technologies SA
33, avenue du Dr. Georges Levy,
Venissieux Cedex, PARC CLUB DU M